COX-2 and beyond: Approaches to prostaglandin inhibition in human disease.
about
High-affinity inhibitors of human NAD-dependent 15-hydroxyprostaglandin dehydrogenase: mechanisms of inhibition and structure-activity relationshipsCysteinyl leukotriene 2 receptor and protease-activated receptor 1 activate strongly correlated early genes in human endothelial cellsPulmonary embolism in a woman taking oral contraceptives and valdecoxibNovel insights into the regulation of cyclooxygenase-2 expression by platelet-cancer cell cross-talkCyclooxygenase-2 in epilepsy.Regulation of genes in the arachidonic acid metabolic pathway by RNA processing and RNA-mediated mechanismsHepatitis C virus core protein suppresses NF-kappaB activation and cyclooxygenase-2 expression by direct interaction with IkappaB kinase betaThe cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confoundingA novel electron paramagnetic resonance-based assay for prostaglandin H synthase-1 activityPrimer: managing NSAID-induced ulcer complications--balancing gastrointestinal and cardiovascular risksEffects of selective cyclooxygenase isoform inhibition on systemic prostacyclin synthesis and on platelet function at rest and after exercise in healthy volunteersAdditive effect of ethanol and HCV subgenomic replicon expression on COX-2 protein levels and activityNonsteroidal Anti-Inflammatory Drugs and the KidneyPGH1, the precursor for the anti-inflammatory prostaglandins of the 1-series, is a potent activator of the pro-inflammatory receptor CRTH2/DP2Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular functionSpinal inflammatory hyperalgesia is mediated by prostaglandin E receptors of the EP2 subtype.Gene expression changes in mononuclear cells in patients with metabolic syndrome after acute intake of phenol-rich virgin olive oilA forced titration study of the antioxidant and immunomodulatory effects of Ambrotose AO supplement.Cyclooxygenase-2-dependent prostacyclin formation and blood pressure homeostasis: targeted exchange of cyclooxygenase isoforms in mice.The influence of Cox-2 and bioactive lipids on hematological cancers.Enhanced prostacyclin formation and Wnt signaling in sclerostin deficient osteocytes and bone.Analgesic and anti-inflammatory properties of novel, selective, and potent EP4 receptor antagonists.Tubuloglomerular feedback is decreased in COX-1 knockout mice after chronic angiotensin II infusion.Amyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids.Selective cyclooxygenase-2 inhibition directly increases human vascular reactivity to norepinephrine during acute inflammation.Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities.Comparison between 3-Nitrooxyphenyl acetylsalicylate (NO-ASA) and O2-(acetylsalicyloxymethyl)-1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (NONO-ASA) as safe anti-inflammatory, analgesic, antipyretic, antioxidant prodrugs.Thematic review series: systems biology approaches to metabolic and cardiovascular disorders. Lipidomics: a global approach to lipid analysis in biological systems.Cardiovascular Risk of Nonsteroidal Anti-Inflammatory Drugs: An Under-Recognized Public Health Issue.Common secondary causes of resistant hypertension and rational for treatmentCinnamon extract suppresses experimental colitis through modulation of antigen-presenting cells.Many putative endocrine disruptors inhibit prostaglandin synthesis.Prostanoid signaling: dual role for prostaglandin E2 in neurotoxicity.Expression of COX-2 in platelet-monocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signalingCardiorenal Effects of Newer NSAIDs (Celecoxib) versus Classic NSAIDs (Ibuprofen) in Patients with Arthritis.Neuroprotection in a rabbit model of intraventricular haemorrhage by cyclooxygenase-2, prostanoid receptor-1 or tumour necrosis factor-alpha inhibition.Antagonism of the antithrombotic and anti-atherosclerotic actions of aspirin by rofecoxib in the cholesterol-fed rabbitResolvins and protectins in inflammation resolution.Platelet-leukocyte interactions link inflammatory and thromboembolic events in ischemic stroke.Platelet microparticles are internalized in neutrophils via the concerted activity of 12-lipoxygenase and secreted phospholipase A2-IIA
P2860
Q21136072-81D9EBE8-9D8A-4D4E-A733-103D2B549590Q24546541-A14C2E0A-BF02-4EB6-BC3A-2B1C5D96B61CQ24815773-6E203048-201D-4260-A85C-BC76E51245D3Q26778352-F0ED5A37-B3CE-4093-AEA8-185824EF26D1Q26827095-F87FBFFE-4F5D-4619-B4C8-A9ED696DFE42Q26849624-C132C272-F3AC-42EE-B064-C8C87B4E1C80Q27469813-345ABD9E-246E-4CB7-B706-234D4EF0C9BBQ28177082-50A5333C-508A-48C8-9AC9-6B8B164E2BE4Q28200568-88469924-95BA-4860-B0AB-B413C1BAFF1FQ28200571-63BD2B6A-B821-4E82-862C-0B2F5E75AC02Q28218884-C14C51D0-25FB-4703-A694-E523654582EEQ28219414-2029D9DB-14F7-4A64-A81F-72B80ADDAA5FQ28386844-050B3937-3D0A-4E84-80B2-A8DF30CC287BQ28731227-F036F0C7-E588-47FA-8ECB-653C7585968EQ30477135-B4DE859D-0699-4E9C-B81F-20886B0AFC83Q30856262-BDB9FD73-B7C1-4C45-B0B2-915A7D36AA32Q33560377-322CB89D-D4D2-4AD3-9F80-1D541A4A7D95Q33569181-C014B7AD-CA8F-48FB-AED0-70C6308FE624Q33639514-0DA0E397-701C-4E23-A112-29A5884665ACQ33688673-87FA4D3E-8457-46F8-9014-5B73051DA359Q33737865-B12262FE-F84D-4E01-A93D-E1DD60CB567CQ33777968-144329BC-5FB2-4924-B15E-B4B0198213B0Q33784000-D3E1688A-508B-4940-B15E-E780FA007EAAQ33914305-4404CBE6-3EEF-49DA-9569-934C1020B331Q34014380-918383D0-86A5-4397-881E-24B189DFB2ECQ34245387-2B84C980-FFF8-4464-8298-3751AEA91229Q34257599-4DD84BDE-AA1A-43F7-9FFD-DB0DE65929DDQ34556407-344835C6-B3A0-4714-B7B7-719940599BE2Q34556489-DBF82B2F-CDF9-46B0-9A60-F4F31064B009Q34669789-CE5B2B4C-F16A-41FD-9DD5-FF5089DEE195Q34670989-DD85EAF7-5261-48FC-9BB2-43269F101F36Q34834713-DD5E9391-E3F9-43C0-ACF7-61E8BE5C568DQ34954633-DA4151E3-7E37-427D-B7F2-A6373B3DDD8AQ35039893-0A37EBA4-44B5-4849-8D16-2AA35A380C94Q35102135-8586AACC-9BAA-43A1-98E7-5F4CC3DEF5C7Q35116500-0C3C07CB-9219-44CB-9717-5BF5A88E8CB4Q35287418-3E811118-B923-43B9-99BE-2D731419DF32Q35332873-DE238F35-8B06-4746-873E-8ED1F4B89313Q35633718-7E0101AD-DE7A-4AD1-A31C-D871AE5AE90DQ35845952-47D39A41-4C49-459E-AA3C-02A5B5F19B20
P2860
COX-2 and beyond: Approaches to prostaglandin inhibition in human disease.
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
COX-2 and beyond: Approaches to prostaglandin inhibition in human disease.
@ast
COX-2 and beyond: Approaches to prostaglandin inhibition in human disease.
@en
COX-2 and beyond: Approaches to prostaglandin inhibition in human disease.
@nl
type
label
COX-2 and beyond: Approaches to prostaglandin inhibition in human disease.
@ast
COX-2 and beyond: Approaches to prostaglandin inhibition in human disease.
@en
COX-2 and beyond: Approaches to prostaglandin inhibition in human disease.
@nl
prefLabel
COX-2 and beyond: Approaches to prostaglandin inhibition in human disease.
@ast
COX-2 and beyond: Approaches to prostaglandin inhibition in human disease.
@en
COX-2 and beyond: Approaches to prostaglandin inhibition in human disease.
@nl
P356
P1476
COX-2 and beyond: Approaches to prostaglandin inhibition in human disease.
@en
P2093
Garret A FitzGerald
P2888
P304
P356
10.1038/NRD1225
P577
2003-11-01T00:00:00Z
P6179
1052083851